| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
β-Amyloid (Aβ) aggregation. BSBM7 is an inhibitor of Aβ aggregation and neuronal toxicity. By inhibiting the aggregation of Aβ peptides, it may prevent the formation of toxic oligomers and fibrils that are implicated in the pathogenesis of Alzheimer's disease.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
BSBM7 inhibits Aβ aggregation and neuronal toxicity in vitro. It prevents the formation of Aβ aggregates and protects neurons from Aβ-induced toxicity. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. |
| ln Vivo |
In vivo activity data for BSBM7 is limited as the compound is primarily used as a research tool for in vitro studies of Aβ aggregation and neurotoxicity. The compound's ability to inhibit Aβ aggregation suggests potential for in vivo studies in animal models of Alzheimer's disease. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
In vitro assays for BSBM7 involve measuring its ability to inhibit Aβ aggregation. Aβ peptides are incubated with various concentrations of BSBM7, and aggregation is monitored using thioflavin T fluorescence or other methods. The compound's ability to prevent the formation of Aβ fibrils and oligomers is assessed. Neuronal toxicity assays measure the protection of cultured neurons from Aβ-induced cell death.
|
| Cell Assay |
Cellular assays for BSBM7 involve treating neuronal cell cultures with Aβ peptides in the presence or absence of the compound and measuring cell viability and neurotoxicity. Neurons are treated with Aβ and various concentrations of BSBM7, and cell viability is assessed using metabolic assays such as MTT. The compound's ability to protect neurons from Aβ-induced toxicity is evaluated.
|
| Animal Protocol |
In vivo animal studies for BSBM7 are limited as the compound is primarily used as a research tool for in vitro applications. The compound's ability to inhibit Aβ aggregation and neuronal toxicity suggests potential for in vivo studies in transgenic mouse models of Alzheimer's disease. Further studies are needed to fully characterize its in vivo efficacy.
|
| ADME/Pharmacokinetics |
BSBM7 has a molecular weight of 508.56 and a molecular formula of C₂₂H₂₄N₂O₈S₂. It has a relative density of 1.422 g/cm³ (Predicted). The compound is soluble in DMSO (22.5 mg/mL). For storage, powder should be kept at -20°C for up to 3 years, away from moisture, and in solvent at -80°C for up to 1 year.
|
| Toxicity/Toxicokinetics |
BSBM7 is an inhibitor of Aβ aggregation and neuronal toxicity. As a research compound, comprehensive toxicological evaluation for clinical development is not available. The compound is for research use only.
|
| References | |
| Additional Infomation |
BSBM7 (N,N'-di(benzyloxycarbonyl)-L-cystine, (Z-Cys-OH)₂) is a dipeptide consisting of two cysteine amino acids linked by a disulfide bond. It functions as an inhibitor of β-amyloid (Aβ) aggregation and neuronal toxicity. BSBM7 is used as a research tool in the study of Alzheimer's disease and other neurodegenerative conditions associated with Aβ aggregation.
|
| Molecular Formula |
C22H24N2O8S2
|
|---|---|
| Molecular Weight |
508.56
|
| Exact Mass |
508.097
|
| CAS # |
6968-11-2
|
| PubChem CID |
95142
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
766.1±60.0 °C at 760 mmHg
|
| Melting Point |
118-122 °C (dec.)
|
| Flash Point |
417.1±32.9 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.630
|
| LogP |
6.01
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
34
|
| Complexity |
613
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PTRQEEVKHMDMCF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H24N2O8S2/c25-19(26)17(23-21(29)31-11-15-7-3-1-4-8-15)13-33-34-14-18(20(27)28)24-22(30)32-12-16-9-5-2-6-10-16/h1-10,17-18H,11-14H2,(H,23,29)(H,24,30)(H,25,26)(H,27,28)
|
| Chemical Name |
3-[[2-carboxy-2-(phenylmethoxycarbonylamino)ethyl]disulfanyl]-2-(phenylmethoxycarbonylamino)propanoic acid
|
| Synonyms |
BSBM 7; BSBM-7; BSBM7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9663 mL | 9.8317 mL | 19.6634 mL | |
| 5 mM | 0.3933 mL | 1.9663 mL | 3.9327 mL | |
| 10 mM | 0.1966 mL | 0.9832 mL | 1.9663 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
